Meeting
2017 Gastrointestinal Cancers Symposium
Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC).
Authors
Ivonne Haffner
University Leipzig, Leipzig, Germany
Ivonne Haffner , Birgit Luber , Dieter Maier , Albrecht Kretzschmar , Ludwig Fischer von Weikersthal , Miriam Ahlborn , Jorge Riera-Knorrenschild , Beate Rau , Florian Weissinger , Stefan Fuxius , Steffen Neumann , Thomas Decker , Katrin Schierle , Christian Wittekind , Florian Lordick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT02305043
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 12)
DOI
10.1200/JCO.2017.35.4_suppl.12
Abstract #
12
Poster Bd #
D12
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.
First Author: Julien Mazières
Poster
2015 Gastrointestinal Cancers Symposium
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071).
First Author: Markus Hermann Moehler
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
First Author: Zhi Peng
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura